May 5th 2025
To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
The revolution in cancer care cannot happen just in the laboratory—it must also take place among stakeholders who must agree on new models for financing very expensive life-saving therapies. The new issue of Evidence-Based Oncology™ looks at the people trying to change the way we pay for cures and their work.
Read More
Impact of Clinical Training on Recruiting Graduating Health Professionals
A business case is made for medical centers to offer high-quality clinical training experiences to recruit graduating health professionals.
Read More
Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics
Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.
Read More
What We're Reading: Insulin Costs Double; PhRMA's Record Spending; Causes of Liver Transplants
January 23rd 2019Between 2012 and 2016, insulin costs for patients nearly doubled while utilization remained flat; the pharmaceutical industry's lead lobbying group spent a record amount in 2018; and alcohol-associated liver disease has surpassed hepatitis C as the top cause of liver transplants.
Read More
Allison Brennan: Compared With Other Models, ACOs Show Increasingly Positive Results
January 4th 2019With a number of difference payment programs being tested, it’s important to have a sophisticated evaluation of these programs to really understand their impact on quality and cost, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Watch
Cost of Pharmacotherapy for Opioid Use Disorders Following Inpatient Detoxification
The mean 24-week cost per participant was $5416 for extended-release injectable naltrexone (57% detoxification, 37% medication, 6% provider/patient) and $4148 for buprenorphine-naloxone (64% detoxification, 12% medication, 24% provider/patient).
Read More
Food Insecurity, Healthcare Utilization, and High Cost: A Longitudinal Cohort Study
September 10th 2018In a longitudinal study, the authors find that food insecurity is associated with greater emergency department visits, inpatient admissions, and length of stay. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.
Read More